<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845181</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PBF-2012-163</org_study_id>
    <secondary_id>2012-005305-44</secondary_id>
    <nct_id>NCT01845181</nct_id>
  </id_info>
  <brief_title>&quot;First-in-human&quot; Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled &quot;First-in-human&quot; Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-680 in Male Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palo Biofarma, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, single-center, randomized, double-blind, dose escalation study without&#xD;
      therapeutic benefit, in which PBF-680 will be administered as single oral ascending dose to&#xD;
      young male healthy volunteers. Up to four different rising doses will be tested in groups of&#xD;
      8 participants. Thus, four groups will participate but each one participating only once. For&#xD;
      each dose level / group the participants will be randomized to active or placebo with 2&#xD;
      participants being randomly assigned to placebo and 6 to the active drug. First, one&#xD;
      volunteer will receive active drug (subgroup 1); after 48h of safety and tolerability&#xD;
      assessment a second subgroup of 3 volunteers will receive 2 active drug and 1 placebo; after&#xD;
      48h of safety and tolerability parameters assessment a third subgroup of 4 volunteers will&#xD;
      receive 3 active drug and 1 placebo. After evaluation of safety parameters of dose level the&#xD;
      process will replicate one week afterwards in the following dosages.&#xD;
&#xD;
      The aims of this study are:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      - To assess the safety and tolerability of single escalating oral doses of PBF-680 in young&#xD;
      male healthy subjects leading to the determination of the maximum tolerated dose (MTD).&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To assess the pharmacokinetics of PBF-680 after single rising oral doses in healthy&#xD;
           young male subjects.&#xD;
&#xD;
        -  To asses the preliminary pharmacodynamic effects.&#xD;
&#xD;
        -  To evaluate the adenosine A1 receptor antagonism in blood samples of healthy volunteer&#xD;
           caused by the PBF-680 administration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to assess the safety and tolerability of single escalating oral doses of PBF-680,&#xD;
      safe measurements (ECG, vital signs, blood chemistry and hematology) will be conducted&#xD;
      before, during and follow-up study course.&#xD;
&#xD;
        -  Physical Examination. Physical examination data will be collected at screening and at&#xD;
           the end of the study. All occurring abnormalities will be displayed by subjects. Vital&#xD;
           Signs. Vital signs (DINAMAP V100) including measurements of blood pressure, pulse and&#xD;
           respiratory rate and digital axillary temperature will be obtained at screening, during&#xD;
           study and at study completion (follow up). All occurring abnormalities will be displayed&#xD;
           by subjects.&#xD;
&#xD;
        -  Adverse Events. All information obtained on adverse events will be displayed and tallied&#xD;
           by treatment /dose. Laboratory variables (Hematology, Biochemistry and Urinalysis):&#xD;
           Clinical laboratory data will be collected at screening, during study and at study&#xD;
           completion(follow up). All subjects with values outside of the normal range for any&#xD;
           variable will be identified. All occurring abnormalities will be displayed by subjects.&#xD;
&#xD;
        -  Electrocardiographic Evaluation. An electrocardiogram will be performed at several&#xD;
           times, at screening, during the study and at completion of the study (follow up).&#xD;
           Description of ECG intervals will be also done. All occurring abnormalities will be&#xD;
           identified.&#xD;
&#xD;
      Also, as secondary variables will be evaluated:&#xD;
&#xD;
        -  Pharmacokinetic profile analysis. The variable for the pharmacokinetic evaluation will&#xD;
           be the parameter that defines the bioavailability in extend and rate Ln [AUC 0t](AUC:&#xD;
           area under curve), Ln [Cmax] of experimental products and placebo. For this purpose the&#xD;
           necessary kinetic parameters will be determined by means of a non compartmental method&#xD;
           with the values obtained after the quantitative analysis of the plasma levels of&#xD;
           PBF-680. The following pharmacokinetic parameters will be obtained from each individual&#xD;
           plasma concentration versus time profile using standard methods, if the data warrant&#xD;
           doing so&#xD;
&#xD;
        -  Pharmacodynamic effects. To asses the preliminary pharmacodynamic effects of PBF-680 at&#xD;
           each dose level, subjective tests (VAS) and (LSEQ) before and after different times&#xD;
           post-drug administration will be conducted. Effects on the CNS (Central Nervous system)&#xD;
           will be evaluated by analyzing of the changes observed in the different time for&#xD;
           subjective assessment scales.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>up to 5-7 days post-dose administration</time_frame>
    <description>Safety and Tolerability evaluation&#xD;
To assess the safety and tolerability of single escalating oral doses of PBF-680, safe measurements: ECG, vital signs, blood chemistry and hematology, will be conducted before, during and follow-up study course.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile analysis</measure>
    <time_frame>pre-dose; +10 min, + 20 min; + 40 min; + 60 min; + 1.5h; + 2 h; + 2.5 h; + 3 h; + 4h; + 8h; + 12h; + 16h; and + 24h post-dose administration and after recording vital signs.</time_frame>
    <description>The main variable for the pharmacokinetic evaluation will be the parameter that defines the bioavailability in extend and rate Ln [AUC 0t], Ln [Cmax] of experimental products and placebo.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dose Level I - Group A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level II - Group B - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg: 1 capsule of 20 mg PBF-680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level II - Group B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level I - Group A - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg: 2 capsules of 5 mg PBF-680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level III - Group C - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg: 2 capsules of 20 mg PBF-680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level III - Group C - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level IV - Group D - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg: 3 capsules of 20 mg PBF-680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level IV - Group D - Palcebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBF-680</intervention_name>
    <description>Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).</description>
    <arm_group_label>Dose Level I - Group A - Active</arm_group_label>
    <arm_group_label>Dose Level II - Group B - Active</arm_group_label>
    <arm_group_label>Dose Level III - Group C - Active</arm_group_label>
    <arm_group_label>Dose Level IV - Group D - Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 or 2 or 3 capsules of placebo.</description>
    <arm_group_label>Dose Level I - Group A - Placebo</arm_group_label>
    <arm_group_label>Dose Level II - Group B - Placebo</arm_group_label>
    <arm_group_label>Dose Level III - Group C - Placebo</arm_group_label>
    <arm_group_label>Dose Level IV - Group D - Palcebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet all of the following inclusion criteria at the pre-study screening&#xD;
        visit (within 4 weeks prior to dosing) in order to participate in this study.&#xD;
&#xD;
          -  Healthy male subjects, 18-45 years of age.&#xD;
&#xD;
          -  Clinically acceptable blood pressure and pulse rate in supine and standing position.&#xD;
             Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.&#xD;
&#xD;
          -  Body weight within normal range (Quetelet's index between 19 and 26) expressed as&#xD;
             weight (kg) / height (m2).&#xD;
&#xD;
          -  Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine&#xD;
             patches, etc., for 6 months prior to the administration of the study medication).&#xD;
&#xD;
          -  Able to understand the nature of the study and comply with all their requirements.&#xD;
&#xD;
          -  Free acceptance to participate in the study by obtains signed informed consent form&#xD;
             approved by the Ethics Committee of the Hospital (CEIC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria at screening will be excluded from entry&#xD;
        into the study:&#xD;
&#xD;
          -  History of serious adverse reactions or hypersensitivity to any drug.&#xD;
&#xD;
          -  Presence or history of allergies requiring acute or chronic treatment (except seasonal&#xD;
             allergic rhinitis).&#xD;
&#xD;
          -  Background or clinical evidence of chronic diseases.&#xD;
&#xD;
          -  Acute illness two weeks before drug administration.&#xD;
&#xD;
          -  Having undergone major surgery during the previous 6 months.&#xD;
&#xD;
          -  History of alcohol or drug abuse in the last 5 years or daily consumption of alcohol &gt;&#xD;
             40 g for men or high consumption of stimulating beverages (&gt; 5 coffees, teas or coca&#xD;
             cola drinks/ day)&#xD;
&#xD;
          -  Abnormal physical findings of clinical significance at the screening examination or&#xD;
             baseline which would interfere with the objectives of the study.&#xD;
&#xD;
          -  Need of any prescription medication within 14 days prior to the administration of the&#xD;
             drug and non prescription medication or herbal medicines within 7 days prior to the&#xD;
             administration of the drug.&#xD;
&#xD;
          -  Participation in other clinical trials during the previous 90 days in which an&#xD;
             investigational drug or a commercially available drug was tested.&#xD;
&#xD;
          -  Having donated blood during 3 month period before inclusion in the study.&#xD;
&#xD;
          -  Existence of any surgical or medical condition which might interfere with the&#xD;
             absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or&#xD;
             hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of&#xD;
             pronounced constipation or diarrhea or conditions associated with total or partial&#xD;
             obstruction of the urinary tract.&#xD;
&#xD;
          -  12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc (corrected&#xD;
             QT interval) ≥ 440 msec, bradycardia (&lt;50 bpm) or clinically significant minor ST wave&#xD;
             changes or any other abnormal changes on the screening ECG.&#xD;
&#xD;
          -  Symptoms of a significant somatic or mental illness in the four week period preceding&#xD;
             drug administration.&#xD;
&#xD;
          -  History of hepatitis B and / or C and / or positive serology results which indicate&#xD;
             the presence of hepatitis B and / or C.&#xD;
&#xD;
          -  Positive results from the HIV serology.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values (as determined by the Principal&#xD;
             Investigator) at the screening evaluation.&#xD;
&#xD;
          -  Positive results of the drug screening the day before starting treatment period.&#xD;
&#xD;
          -  Known hypersensitivity to the study drug or the composition of the galenical form&#xD;
&#xD;
          -  History of psychiatric diseases or epileptic seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa M Antonijoan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palobiofarma S.L. (molecule owner)</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08302</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIM-Sant Pau. Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenosine A1 receptor antagonist</keyword>
  <keyword>Asthma</keyword>
  <keyword>adenosine receptor modulator</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

